locally advanced pancreatic cancer
Conditions
Interventions
S1: bid d1-15 q3w x 3 courses 60mg/sq PO GEM: d1 and d1, q3w x 3 courses 1000mg/sq DIV
Sponsors
Faculty of Medicine, Kyoto University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Histologically proven pancreatic adenocarcinoma 2)UICC stageIII with one of the criteria below; a)tumor abutment of the SMA involving half of the artery circumference b)encasement of a short segment of HA without tumor extension to the celiac axis 3)No prior chemotherapy or radiotherapy 4)Age above 20 5)ECOG performance status of 0 or 1 6)Adequate hematologic, hepatic and renal function 7)Written informed consent
Exclusion criteria
Exclusion criteria: 1)Watery diarrhea 2)Severe mental disorder 3)Active infection 4)Severe complications, such as ileus, heart failure and renal failure 5)Symptomatic pulmonary fibrosis or interstitial pneumonia 6)History of radiation therapy to the chest 7)Marked pleural or peritoneal effusion 8)Active concomitant malignancy 9)Treatment with phenytoin, potassium warfarin or flucytosine
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| pathologically margin negative status | — |
Secondary
| Measure | Time frame |
|---|---|
| response rate, toxicity, progression free survival, overall survival | — |
Countries
Japan
Outcome results
None listed